Table 1.
Clinical characteristics
| Patient | P01 | P02 | P03 | P04 | P05 | P07 | P08 | P09 | P10 | P11 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | 31 | 78 | 71 | 58 | 54 | 39 | 68 | 73 | 63 | 60 |
| Sex | M | M | M | F | M | F | M | F | M | M |
| Ethnicity | White | White | White | White | Black | Asian | Other | Asian | Black | White |
| Treatment type | Surgery LG | Surgery HG | Surveillance LG, biopsy on progression† | Surgery LG | Surgery LG† | Surveil-lance LG; Surgery† | Surgery HG | Surgery HG | Surgery HG | Surveil-lance LG; Surgery |
| Elective debulk | Elective debulk | Biopsy on transformation; chemoradiotherapy | Elective debulk | Biopsy; 1 cycle chemotherapy | Debulk; chemoradiotherapy | Debulk; chemoradiotherapy | Debulk | Debulk; chemoradiotherapy | Complete debulk; chemoradiotherapy | |
| Time (days) between FPIA and surgery | 33 | 4 | 107 | 1 | 16 | 101 | 10 | 11 | 2 | 75 |
| Number of samples taken for histology | 8 | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 |
| Histopathology (including % expression in neoplastic cells) | Diffuse astrocytic, Ki67 4%, p53 20% | Astrocytic, Ki67 15–20%, p53 > 20% | Diffuse astrocytic, Ki67 5%, p53 widespread expression | Diffuse glioma, Ki67 15–20% | Diffuse astrocytic, Ki67 2%, focal areas of early transformation | Oligodendroglioma, Ki67 8%, p53 5% | Cellular glial tumour with astrocytic morphology, Ki67 15%, p53 overexpressed > 20% | Astrocytic, primitive neuronal components, Ki67 > 50%, p53 diffuse expressed | Cellular glial tumour with astrocytic morphology, Ki67 15%, p53 focal overexpressed | Oligodendroglioma, Ki67 10%, p53 not overexpressed |
| WHO grade histology | II LGG astrocytoma | IV HG GBM | III astrocytoma | IV HG GBM | II L–focal areas of early transformation | Mixed II and III | IV HG GBM | IV HG GBM | IV HG GBM | II LGG oligodendroglioma |
| WHO grade patient | II LGG | IV HGG | III astrocytoma | IV HGG | III astrocytoma | III oligodendroglioma | IV HGG | IV HGG | IV HGG | II oligodendroglioma |
| Routine CE-MRI (CE-T1 MRI and T2 FLAIR) for initial staging | LGG | HGG | LGG but transformed on surveillance – HGG | HGG | HGG | LGG | HGG | HGG | HGG | LGG |
| Molecular phenotype | IDH1mu; ATRX loss; p53mu, 1p/19q aneuploidy | IDHwt; MGMT-methylated; ATRXwt, p53wt | IDH1mu; ATRX loss; p53 mu | IDH1wt; MGMT unmethylated; p53wt;; EGFR-VIIImu, 1p/19q aneuploidy | IDH1mu; ATRXmu; p53mu, 1p/19q aneuploidy; 1p/19q del in an aneuploid clone | IDH1mu; ATRX loss; p53wt, 1p/19q del | IDH1wt; ATRwt;; p53mu, MGMT unmethylated; TERTmu; pTENmu; CDK4 amplification | IDH1wt; ATRXwt,; p53 mu, MGMT methylated > 25%; TERTmu; pTENmut | IDH1/2wt; p53wt; MGMT methylation low < 5%, TERT mu; | IDH1mu; ATRXwt; p53wt; 1p/19q del; TERT mu; |
| Overall survival (months) | 64 | 1.6 | 61.2 | 7.05 | 42 | 29.03 | 5.5 | 3 | 13.7 | 25 |
†Progressed or reclassified – originally surveillance for LGG
LGG, lower-grade glioma; HGG, higher-grade glioma